ASRT Assertio Therapeutics Inc.

0.68
+0.01  (+2%)
Previous Close 0.67
Open 0.67
Price To Book 0.96
Market Cap 55,298,496
Shares 81,297,406
Volume 816,008
Short Ratio
Av. Daily Volume 1,826,447
Stock charts supplied by TradingView

NewsSee all news

  1. ZYNGA INC (FormDEF 14A) (0001564590-20-015517)

  2. Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

    Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating

  3. Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024

    LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announces that it has commenced cash tender offers (the "Offers") to purchase any and

  4. Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results

     -- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid in

  5. Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020

    LAKE FOREST, Ill., March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it will release fourth quarter and full year 2019 financial results on

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved January 28, 2011.
GRALISE
Postherpetic neuralgia - shingles
CRL issued May 31, 2013.
SEFELSA
Hot flashes
CRL announced October 21, 2019.
Cosyntropin depot
Adrenocortical insufficiency screening

Latest News

  1. ZYNGA INC (FormDEF 14A) (0001564590-20-015517)

  2. Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products

    Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating

  3. Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024

    LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announces that it has commenced cash tender offers (the "Offers") to purchase any and

  4. Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results

     -- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid in

  5. Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020

    LAKE FOREST, Ill., March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it will release fourth quarter and full year 2019 financial results on

  6. Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt

    LAKE FOREST, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or "The Company") (NASDAQ:ASRT), today announced it has entered into separate, privately negotiated agreements (the "Purchase

  7. Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

    LAKE FOREST, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or "The Company") (NASDAQ:ASRT), today announced the closing of its previously disclosed definitive agreement ("Agreement")

  8. Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million

    Company Intends to Use Cash Proceeds to Retire its Outstanding Debt Company Intends to Use Improved Balance Sheet to Pursue Business Development, Strategic Partnerships and Investment Opportunities LAKE

  9. Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance

    LAKE FOREST, Ill., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. ("Assertio" or "The Company") (NASDAQ:ASRT), today announced the closing of its previously disclosed agreement ("Agreement") with

  10. Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

    LAKE FOREST, Ill., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that members of senior management will participate at the 31st Annual Piper Jaffray Healthcare Conference

  11. Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference

    LAKE FOREST, Ill., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that members of senior management will participate at the Stifel Healthcare Conference in a session

  12. Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600

    NEW YORK, Oct. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Tuesday, November 5: Ceridian

  13. Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019

    LAKE FOREST, Ill., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release third-quarter 2019 financial results on Wednesday, November 6, 2019, after the close

  14. Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin

    LAKE FOREST, Ill., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT), today announced that its development partner West Therapeutic Development, LLC (West) has received a Complete Response

  15. Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors

    LAKE FOREST, Ill., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) announced today that Dr. David Wheadon has been appointed to the Company's Board of Directors. Dr. Wheadon is a former

  16. Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference

    LAKE FOREST, Ill., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that members of senior management will participate at the Annual Cantor Fitzgerald Global Healthcare

  17. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical stage

  18. Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes

    Announces Results of Annual Meeting of Shareholders TORONTO and HOUSTON, Sept. 24, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTCQB:MDNAF), a clinical